SCHEMBL523736

SCHEMBL523736

c1ccc(-c2nccc(N3CC4CC4C3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.46
ALDH1A1 P00352 3/20 0.45
CYP1A2 P05177 3/20 0.45
HSD17B10 Q99714 3/20 0.45
CYP3A4 P08684 2/20 0.45
CLK4 Q9HAZ1 2/20 0.45
CYP2D6 P10635 2/20 0.45
TSHR P16473 1/20 0.45
COMT P21964 1/20 0.44
PDE10A Q9Y233 2/20 0.43
PIK3CD O00329 1/20 0.43
PIK3CA P42336 1/20 0.43
USP2 O75604 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
SORD Q00796 1/20 0.40
ALOX15 P16050 1/20 0.40
SYK P43405 1/20 0.39
HTT P42858 1/20 0.39
HCRTR1 O43613 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2381878 0.75 CYP1A2 (0.74) HRH3ALDH1A1CYP1A2HSD17B10CYP3A4
Hydrochloric Acid SCHEMBL3269944 0.74 CYP1A2 (0.60) HRH3ALDH1A1CYP1A2HSD17B10CYP3A4
SCHEMBL30516986 0.74 OGA (0.51) ALDH1A1CYP1A2HSD17B10CYP3A4CLK4
SCHEMBL30556650 0.71 GRIN2B (0.59) ALDH1A1CYP3A4CYP2D6
SCHEMBL17609895 0.70 TRPA1 (0.41)
SCHEMBL1672390 0.69 HCRTR1 (0.50) HCRTR1HCRTR2
SCHEMBL8887155 0.68 COMT (0.43) ALDH1A1CYP1A2HSD17B10CYP3A4CLK4
SCHEMBL21861425 0.67 TRPA1 (0.47) ALDH1A1CYP1A2HSD17B10CYP3A4CYP2D6
SCHEMBL628460 0.67 MTOR (0.51) HRH3ALDH1A1CYP1A2HSD17B10CYP3A4
SCHEMBL2383996 0.67 CYP1A2 (0.66) HRH3ALDH1A1CYP1A2HSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2417128-B1 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES AS ADP RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2016-03-02 EP disclosed
EP-2417128-B1 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES AS ADP RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2016-03-02 EP disclosed
CN-102369197-B 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines used as ADP receptor antagonists ACTELION PHARMACEUTICALS LTD 2013-11-06 CN disclosed
CN-102369197-B 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines used as ADP receptor antagonists ACTELION PHARMACEUTICALS LTD 2013-11-06 CN disclosed
US-8288385-B2 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-16 US disclosed
US-8288385-B2 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-16 US disclosed
US-8288385-B2 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-16 US disclosed
CN-102369197-A 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines used as adp receptor antagonists ACTELION PHARMACEUTICALS LTD 2012-03-07 CN disclosed
CN-102369197-A 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines used as adp receptor antagonists ACTELION PHARMACEUTICALS LTD 2012-03-07 CN disclosed
EP-2417128-A2 6-(3-AZA-BICYCLOÝ3.1.0¨HEX-3-YL)-2-PHENYL-PYRIMIDINES Actelion Pharmaceuticals Ltd. (CH) 2012-02-15 EP disclosed
EP-2417128-A2 6-(3-AZA-BICYCLOÝ3.1.0¨HEX-3-YL)-2-PHENYL-PYRIMIDINES Actelion Pharmaceuticals Ltd. (CH) 2012-02-15 EP disclosed
EP-2417128-A2 6-(3-AZA-BICYCLOÝ3.1.0¨HEX-3-YL)-2-PHENYL-PYRIMIDINES Actelion Pharmaceuticals Ltd. (CH) 2012-02-15 EP disclosed
US-20120028989-A1 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES VIATRIS ASIA PACIFIC PTE. LTD. (SG) 2012-02-02 US disclosed
US-20120028989-A1 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES VIATRIS ASIA PACIFIC PTE. LTD. (SG) 2012-02-02 US disclosed
US-20120028989-A1 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES VIATRIS ASIA PACIFIC PTE. LTD. (SG) 2012-02-02 US disclosed
WO-2010116328-A3 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES AS ADP RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2011-01-13 WO disclosed
WO-2010116328-A3 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES AS ADP RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2011-01-13 WO disclosed
WO-2010116328-A2 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES ACTELION PHARMACEUTICALS LTD (CH) 2010-10-14 WO disclosed
WO-2010116328-A2 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES ACTELION PHARMACEUTICALS LTD (CH) 2010-10-14 WO disclosed
WO-2010116328-A2 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES ACTELION PHARMACEUTICALS LTD (CH) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028989-A1 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES P2RY12, P2RY13, P2RY6 HRH3 353/4885ALDH1A1 1662/4885CYP1A2 1420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.